Why the study?
Advancements in reinforcement learning introduced new variants, leading to increased interest in using this approach to address complex issues in diabetes management.
Reinforcement learning provides a dynamic, adaptive artificial intelligence approach to optimizing diabetes management and improving time in range.
Answers are grounded in this paper and cite their sources.
RL shows promise for personalized diabetes management; leaves open need for prospective trials before clinical adoption.
With the advancements in reinforcement learning (RL), new variants of this artificial intelligence approach have been introduced in the literature. This has led to increased interest in using RL to address complex issues in diabetes management. Using RL, a decision maker (or agent) observes decision-making factors (or state) from the dynamic operating environment, selects actions based on its optimal policy (i.e., a mapping between states and optimal actions), and subsequently receives delayed rewards. The agent adapts its policy to changes in the operating environment to maximize its cumulative reward as time goes by, thereby improving system performance. This paper presents how various variants of RL have been used to improve diabetes management, such as a higher time in range during which the blood glucose level is within the normal range and a higher similarity between RL and physician’s policies. Key highlights focus on the application of RL in diabetes management, including a taxonomy of the attributes of RL (e.g., roles and advantages), essential elements for training (e.g., data and simulators), representations of diabetes attributes in RL models, and variants of RL algorithms. In addition, this paper discusses open issues and potential future developments in the use of RL in diabetes management.
No takes yet. Share an insight, caveat, or question.
Yau et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: